Lowe M Patrick, Chamberlain Donald H, Kamelle Scott A, Johnson Peter R, Tillmanns Todd D
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University, Chicago, IL, USA.
Gynecol Oncol. 2009 May;113(2):191-4. doi: 10.1016/j.ygyno.2009.01.018. Epub 2009 Feb 26.
The purpose of the study is to report a multi-institutional experience with robotic-assisted radical hysterectomy to treat patients with early stage cervical cancer with respect to perioperative outcomes.
A multi-institutional robotic surgical consortium consisting of five board-certified gynecologist oncologist in distinct geographical regions of the United States was created to evaluate the utility of robotics for gynecologic surgery (benign and malignant). Between April 2003 and August 2008, a total of 835 patients underwent robotic surgery for benign gynecologic disorders and/or gynecologic malignancies by a surgeon in the consortium. IRB approval was obtained and data was collected in a prospective fashion at each institution. For the purposes of the study, a multi-institutional HIPPA compliant database was then created for all patients that underwent robotic-assisted surgery between the April 2003 and August 2008. This database was queried for all patients who underwent a robotic-assisted type II or III radical hysterectomy for Stage IA1 (+vsi)-IB2 cervical carcinoma. Forty-two patients were identified. Records were then reviewed for demographic data, medical conditions, prior abdominal or pelvic surgeries, and follow-up. The perioperative outcomes analyzed included: operative time (skin-skin), estimated blood loss (EBL), length of hospital stay, total lymph node count, conversion to laparotomy, and operative complications.
From a database of 835 patients who underwent robotic surgery by a gynecologic oncologist, a total of 42 patients who underwent a robotic-assisted type II (n=10) or type III (n=32) radical hysterectomy for early stage cervical cancer were identified. Demographic data demonstrated a median age of 41 and a median BMI of 25.1. With regard to stage, seven patients (17%) were Stage IA2, twenty-eight patients (67%) were Stage IB1 and six patients (14%) were Stage IB2. There was a single patient with Stage IA1 cervical cancer with vascular space invasion who underwent a type II radical hysterectomy. The overall median operative time was 215 min. The overall median estimated blood loss was 50 cc. No patient received a blood transfusion. The median lymph node count was 25. The median hospital stay was 1 day. Positive lymph nodes were detected in 12% of the patients. Pelvic radiotherapy or chemo-radiation was given to 14% of the patients based on final surgical pathology. Intraoperative complications occurred in 4.8% of the patients and included one conversion to laparotomy (2.4%) and one ureteral injury (2.4%). Postoperative complications were reported in 12% of the patients and included a DVT (2.4%), infection (7.2%), and bladder/urinary tract complication (2.4%) The conversion rate to laparotomy was 2.4%.
Robotic-assisted radical hysterectomy is associated with minimal blood loss, a shortened hospital stay, and few operative complications. Operative time and lymph node yields are acceptable. This data suggests that robotic-assisted radical hysterectomy may offer an alternative to traditional radical hysterectomy. This series contributes to the growing literature on robotic-assisted radical hysterectomy and prospective comparisons with traditional radical hysterectomy are needed.
本研究旨在报告多机构开展机器人辅助根治性子宫切除术治疗早期宫颈癌患者的围手术期结果。
成立了一个多机构机器人手术联盟,成员包括美国不同地理区域的五位获得董事会认证的妇科肿瘤学家,以评估机器人技术在妇科手术(良性和恶性)中的应用。2003年4月至2008年8月期间,该联盟的一名外科医生共为835例患有良性妇科疾病和/或妇科恶性肿瘤的患者实施了机器人手术。获得了机构审查委员会的批准,并在每个机构以前瞻性方式收集数据。为了本研究的目的,随后为2003年4月至2008年8月期间接受机器人辅助手术的所有患者创建了一个符合多机构健康保险流通与责任法案(HIPPA)的数据库。查询该数据库,找出所有接受机器人辅助II型或III型根治性子宫切除术治疗IA1期(+脉管浸润)至IB2期宫颈癌的患者。共识别出42例患者。然后审查记录,获取人口统计学数据、医疗状况、既往腹部或盆腔手术情况以及随访信息。分析的围手术期结果包括:手术时间(皮肤切开至皮肤缝合)、估计失血量(EBL)、住院时间、总淋巴结计数、中转开腹以及手术并发症。
在835例由妇科肿瘤学家实施机器人手术的患者数据库中,共识别出42例接受机器人辅助II型(n = 10)或III型(n = 32)根治性子宫切除术治疗早期宫颈癌的患者。人口统计学数据显示,中位年龄为41岁,中位体重指数(BMI)为25.1。在分期方面,7例患者(17%)为IA2期,28例患者(67%)为IB1期,6例患者(14%)为IB2期。有1例IA1期宫颈癌伴脉管浸润的患者接受了II型根治性子宫切除术。总体中位手术时间为215分钟。总体中位估计失血量为50毫升。无患者接受输血。中位淋巴结计数为25个。中位住院时间为1天。12%的患者检测到阳性淋巴结。根据最终手术病理结果,14%的患者接受了盆腔放疗或放化疗。4.8%的患者发生术中并发症,包括1例中转开腹(2.4%)和1例输尿管损伤(2.4%)。12%的患者报告了术后并发症,包括深静脉血栓形成(DVT)(2.4%)、感染(7.2%)和膀胱/尿路并发症(2.4%)。中转开腹率为2.4%。
机器人辅助根治性子宫切除术与失血量极少、住院时间缩短以及手术并发症较少相关。手术时间和淋巴结获取量是可接受的。该数据表明,机器人辅助根治性子宫切除术可能为传统根治性子宫切除术提供一种替代方案。本系列研究为关于机器人辅助根治性子宫切除术的文献不断增加做出了贡献,需要与传统根治性子宫切除术进行前瞻性比较。